To read the full story, subscribe or sign in.

Cautious optimism for Biolinerx’s CXCR4 inhibitor in pancreatic cancer

Dec. 13, 2019

HONG KONG – Israel-based Biolinerx Ltd. has unveiled the latest data from its ongoing phase IIa COMBAT/KEYNOTE-202 study at the European Society of Medical Oncology Immuno-Oncology Congress 2019 which evaluates Biolinerx’s BL-8040, an inhibitor of the chemokine receptor CXCR4.

BioWorld Clinical Cancer

Data needed for Chinese COVID-19 vaccines against Delta variant

BioWorld Asia

The lack of data surrounding the efficacy of Chinese COVID-19 vaccines against the Delta variant has had many questioning them, especially after a recent study...

Data needed for Chinese COVID-19 vaccines against Delta variant

BioWorld

The lack of data surrounding the efficacy of Chinese COVID-19 vaccines against the Delta variant has had many questioning them, especially after a recent study...

Today's news in brief

BioWorld

BioWorld briefs for July 30.

Today's news in brief

BioWorld MedTech

BioWorld MedTech's briefs for July 30.

Aicuris heads for phase III with herpes drug pritelivir

BioWorld

Aicuris Anti-Infective Cures AG is beginning the pivotal phase III part of its trial of pritelivir for herpes simplex virus infection after an encouraging...